IKT Inhibikase Therapeutics Inc
1,865
$1.83
$0.06
(3.17%)
| Watchers | 1,865 |
| 52-Wk Low | $0.79 |
| 52-Wk High | $4.35 |
| Market Cap | $12.24M |
| Volume | 9,217.00 |
| 52-Wk High | $4.35 |
| 52-Wk Low | $0.79 |
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionGlobe Newswire • about 2 months ago
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc...
Share to Feed
Inhibikase Therapeutics ( NASDAQ:IKT ) Full Year 2023 Results Key Financial Results Net loss: US$19.0m (loss widened by...
Related Stocks: NAS:IKT...
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript...
Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript...
Inhibikase Therapeutics GAAP EPS of -$3.57 misses by $0.82, revenue of $0.26M in-line...
Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BOSTON and ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ( Inhibikase or Company ), a clinical-stage pharmaceutical company developing protein kinase...
Company to pursue eleven indications for IkT-001Pro; all previously approved for treatment with imatinib mesylateBOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc...